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Welcome to the first edition of the new styleEONS Newsletter, which aims to reach out
to everyone involved in supporting and caring for
cancer patients.
No professional group is better placed to do this than
the cancer nurses of Europe, because, as our bannerline
indicates, nursing really is at the heart of patient care. It
is our role to understand the many different needs of
each of our nurses on whom patients depend as they
move through their cancer journey.
EONS helps to ensure that the patients’ needs – med-
ical, emotional, spiritual, social and practical – are ad-
dressed, by developing resources with our partner
professionals that educate, support and empower can-
cer nurses, enabling them to provide the best possible
patient care.
The importance of the patient-centred, partnering role
of cancer nurses in a modern health service is gaining
increasing recognition. However, specialist training, pro-
fessional responsibilities and team roles still vary widely
across Europe.
While reaching out to our fellow professionals, the
EONS Newsletter will therefore also continue to show-
case the unique contribution we make to to the health
of European citizens, and provide a strong voice for all
European cancer nurses on the issues that most
closely affect them.
This edition of the Newsletter, which focuses on breast
cancer care, is the first in a series of themed issues.
Touching on subjects from symptom management to
advanced disease, cancer biology, education and train-
ing, adherence and reaching marginalised groups of pa-
tients, it demonstrates just how many different aspects
are involved in the role of the cancer nurse.
The issue was compiled by our guest editor, Debbie
Fenlon, who has strong connections throughout the
cancer nursing field through her long experience work-
ing as a specialist breast care nurse at the Royal Mars-
den Hospital in London and then as a researcher
specialising in the problems that women face once they
have been diagnosed with breast cancer.
Our next edition, winter 2009, will focus on devel-
opments in prostate cancer nursing, followed by an
edition focusing on nursing education across Europe,
in spring 2010.
I hope you enjoy our new style Newsletter and that
you will also take time to explore the relaunched EONS
website www.cancernurse.eu, which has been re-
designed to better serve the needs of our members
while also opening up to everyone involved in support-
ing and caring for cancer patients and their families.
With your help and feedback, we will continue to de-
velop both the Newsletter and the website to ensure that
they keep pace with your changing needs.
Editorial Clair Watts, Executive Director
At the heart ofpatient care
With broad experience of leadership and management in the healthcare field as well as 3.5 years experience as
Executive Director of a European Medical NGO,Clair Watts joined EONS as the Executive Director in April 2009.
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The launch of EONS Breast Care Nursing Curriculumat this year’s ECCO–ESMO Congress in Berlin
marks a milestone in the development of this specialty.
For the first time, Europe has a single set of minimum train-
ing requirements that must be fulfilled in order to qualify as
a breast care nurse. Though the requirements may be mod-
est by the standards of some countries, they set a European
benchmark that defines breast care nursing as a specialty
that is patient-centred and carried out in partnership with the
breast care team, the patient and their family.
The curriculum was drawn up by a panel of experienced
breast care nurses from all over Europe. Some of them have
contributed to this issue of the EONS Newsletter, which
takes a broad look at the many aspects of this profession
and the challenges and developments in the field.
Ilana Kadmon, who set up a breast care nursing service
for the whole of Israel, discusses the need for agreed stan-
dards of education for the next generation. Yvonne
Wengström, past president of EONS and Professor of Cancer
Care and Eva Gustafsson from the Karolinska University Hos-
pital in Sweden, shares thoughts on how to increase
women’s adherence to endocrine treatment. Saskia Claassen,
an advanced nurse practitioner in breast cancer working in
the Catharina hospital in Eindhoven, the Netherlands, takes
part in assessing breast clinics throughout Europe and mak-
ing sure that provision of breast care nursing is adequate. She
gives us an insight into this work. Manuela Eicher, a research
fellow at the University of Basel, Switzerland, describes how
breast care nurses are well placed to respond to the changes
in health care that are occurring throughout Europe.
Other contributions address the many varied aspects of the
breast care nursing role. Mary Woods, consultant nurse in
lymphoedema at the Royal Marsden Hospital in London and
Surrey in the UK, gives us the latest on management of this
condition. Kay Townsend, a lecturer at the University of
Southampton, UK, gives an update on the complexities of
breast cancer cell receptor sites and treatments. We have two
contributions from the UK charity Breast Cancer Care. Emma
Blows describes research about how to reach out to provide
information and support to hard-to-reach groups in the UK,
such as those from black and minority ethnic groups and
older women with breast cancer. Liz Reed and Dora Wheeler
have completed an important piece of work looking at the
needs of women with secondary breast cancer.
This collection of articles show that the needs of breast
cancer patients go well beyond diagnosis and treatment –
their needs are broad ranging and long lasting.
My hope is that our nurse training takes us beyond the
medical model of acute care and treatment and that we
focus on the experience of breast cancer through its diagno-
sis, treatment and on to long-term living. Practising as
breast care nurses, we focus on the needs of the patient,
whatever their needs and agendas are, irrespective of where
they are on the disease trajectory or what treatment they are
having. By doing this, we enable women with breast cancer
to achieve the goals that they set despite the constraints set
upon them by their breast cancer experience.
Guest Editorial Debbie Fenlon
Debbie Fenlon spent 12 years at the Royal Marsden Hospital in London as a nurse specialist working with women
with breast cancer. She is currently a Senior Research Fellow based at the Macmillan Research Unit at the University
of Southampton, where she specialises in cancer survivorship.
Breast care nursing iscoming of age
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6Although summer istraditionally the time forslowing down the pace of work, there’sbeen no summer break for the EONSBoard this year. Since spring, we havelaunched a new website, redesignedour newsletter and renovated the office.We give a very warm welcome to ClairWatts, who joined us in April as ournew executive director, and threw allher energies behind carrying throughthese changes.The new look website is now live atwww.cancernurse.eu. Do please exploreit if you have not already done so.Both the look and content have beenradically updated to ensure that youcan access the very latest informationwith ease. We will continue to refinethe website to ensure it serves theneeds of members and other visitors.Please send any comments andsuggestions to the EONS office(eons.secretariat@cancernurse.eu) sothat we can continue this developmentprocess together.With its project partners, the Board has
continued updating EONS educationalmaterials and developing neweducational projects. The targetprogramme, on the science behindtargeted therapies, has been updatedand relaunched as ‘target Update2009’, with the highly successful firsttraining course taking place in May inDublin, Ireland (see opposite).The curriculum of the BREATHEproject (Breathing and RespiratoryEducation and Training for Healthprofessionals with E technology) isnow in the final stage of production,and will be launched on the EONSwebsite in September.The EONS Specialist Breast CareNursing Post Basic Curriculum hasnow been finalised and will beofficially launched at the ECCO15–ESMO34 congress in Berlin. You canfind out more about EONS projects onthe EONS website.A lot of time has also been put intoplanning the programme for theSpecialist Oncology Nursing track ofthe ECCO–ESMO congress in Berlin, as
well as developing the EONS 7thSpring Congress programme.The members of the Board lookforward to meeting many of you inBerlin and hope that you will find theprogramme as stimulating andinnovative as we do.We also take this opportunity tothank everyone who submittedabstracts for presentation during theECCO–ESMO congress, and we hopethat those who are able to attend thiscongress will join us for a drink duringthe EONS General Meeting on TuesdaySeptember 22nd at 6pm.Your deadline for abstract andfellowship funding submissions for theEONS Spring congress (scheduled forApril 15-16th 2010, in the Hague) hasbeen set as December 17th 2009.We look forward to receiving yoursubmissions and your continuing support.
Ulrika Östlund,
EONS Board Secretary
EONS is on the move!
A message from the Board
EONS Executive Board (from top left) Anita Margulies,
Ulrika Östlund, Daniel Kelly, Kay Leonard, Françoise
Charnay Sonnek, Yvonne Wengström,
Sara Faithfull (President), Sultan Kav (President elect)
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Cancer and sexuality: patients’ questions answered in a Q&A booklet
Sexual dysfunction is a frequentlong-term side-effect of cancertreatment. But patients report that theyseldom remember discussing risks ofsexual dysfunction before treatment orwhat can be done about the problemafter treatment.Although many oncology nurses areaware that patients and their partnerscan have sexual problems, most nursesdo not provide information or supportconcerning sexual matters.Furthermore, sexual difficulties are oftennot identified by the cancer care team, andmost patients receive little or no assistancein dealing with the effects of cancer andits treatment on intimacy. Patients andtheir partners want information regardingthe effects of illness, treatment anddisability on sexuality.In an effort to meet this need, a newinformation booklet has been compiled
in the Netherlands: 80 questions andanswers about cancer and sexuality.The topics cover all cancer treatmentsthat may affect sexuality and fertility,with the aim of making the informationon sexuality accessible andunderstandable to patients with all typesof cancer and their partners.This information may help the patientto discuss expected sexual problems withtheir health care provider, if necessary. Itshould help patients to anticipate theexpected sexual problems of their canceror its treatment and to influence theirquality of life in a favourable way.Research has shown that differentsexuality information is needed atdifferent time periods: at the time ofdiagnosis and treatment, in the recoveryperiod, and when the patient and theirpartner start rebuilding their sexual life.In the near future, hopefully, many
of the sexual problems encounteredmay be prevented by providing adequateinformation and patient education at theright time.In the first edition of the booklet,answers to the 80 questions weredrafted based on the literature andmultidisciplinary expert opinion givenby 26 health care providers.Though there is still a lack ofconsensus- or evidence-basedinformation on sexuality after cancer, astart has been made in collectingstructured feedback frompatients/partners and colleagues in thefield, which will be used to completeand rewrite the booklet.Currently the booklet exists only inDutch, but an English version is planned.
Corien Eeltink and Daniela Hahn
EPE award winners 2009
L ast May, Dublin became the first city tohost the updated target programme, with
a course organised by the Irish Association for
Nurses in Oncology (IANO).
target gives nurses the chance to learn
about the science behind targeted therapies.
When it started, back in 2006, the focus was
principally on therapies for colorectal cancer
targeted at epidermal growth factor receptors
(anti-EGFRs).
But this is a fast-moving field, and over the
past year the target course has been exten-
sively revised to keep up with developments.
target Update 2009 now covers targeted
therapies for all tumour types.
Twenty-nine cancer nurses attended from
oncology units all over Ireland. Well-pitched pre-
sentations ranging from the molecular biology of
cancer to the use of targeted therapies in the
clinical setting gave them valuable insight and
understanding of the types of treatment increas-
ingly used in the patients they care for.
An interactive session at the end of the day
gave participants the chance to share their own
clinical experiences of targeted therapies. Each
received a resource folder of lecture notes to
take back with them.
The revised course received highly positive
feedback from participants, who said the infor-
mation provided was very applicable to their
clinical practice.
A three-month follow-up questionnaire will
be used to find out whether participants were
able to apply their newly acquired knowledge
to their daily practice.
Frieda Clinton, TARGET course organiser, Ireland;
President, Irish Association for Nurses in Oncology
target 2009 programme gets the thumbs up from Ireland
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9Europa Donna – The EuropeanBreast Cancer Coalition, is an inde-pendent non-profit organisation whosemembers are affiliated groups from coun-tries throughout Europe. The coalitionworks to raise awareness of breast cancerand to mobilise the support of Europeanwomen in pressing for improved breast can-cer education, appropriate screening, opti-mal treatment and increased funding forresearch. It does this throughworking at thelevel of local and national authorities aswellas the institutions of the European Union.Founded 15 years ago, Europa Donna hasexpanded from an initial three countries toits current 44.
THE EUROPEAN GUIDELINESThe coalition is committed to ensuring thatall women in Europe have access to breastservices in a specialist breast unit as de-fined by the EU Guidelines for Quality As-surance in Breast Cancer Screening andDiagnosis published in 2006.A key component of this service is thatcare is provided by a multidisciplinaryteam and that women should receive ad-vice, support, and counselling from a spe-cialist breast care nurse, or a core teammember with professional psychologicaltraining who is an integral part of this team.The guidelines made a more general ref-erence to this core team member precisely
because there were no European standardsor curriculum for this specialty that couldbe followed in all European countries. Aworkshop at the Parliament was held in Oc-tober 2006 to discuss the variations in train-ing and definition of this specialty acrossEurope with the aim that EU guidelines forthis should be included in the next editionof the Guidelines.Europa Donna therefore applauds EONSfor responding to this need, carrying outthis research and developing a curriculumdefining the basic module that should be aminimum requirement for all breast carenurses practising across Europe.
Europa Donna believes this represents animportant tool that can be used immediately,adapted as necessary, and that ultimately itwill lead to developing and adopting EUguidelines for breast nursing that can be im-plemented in all European countries.
BREAST HEALTH DAYEuropa Donna launched on October 2008Breast Health Day to disseminate the infor-mation found by recent studies from the In-ternational Agency for Research on Cancer(IARC) about the factors influencing thehealth of the breasts.The coalition decided to embark on amajor breast health campaign/public healtheducation programme and launched breasthealth day on October 15th 2008, which in-cluded a public service announcementtranslated for all member countries.
A NETWORK OF SURVIVORSEuropa Donna is an European advocacyorganisation with European strategy andgoals. From the start, Europa Donna hasdeveloped a network of survivors workingat the national level through the nationalfora. This gives the coalition a strong basefrom which it has been able to make a sig-nificant impact on European institutionsand national health services in terms ofoptimising breast health services.
Further information can be found at:
www.europadonna.org
www.breasthealthday.org
Europa Donna wants every woman with breast cancer to
be treated by a team of specialists with a defined set of
competencies. It welcomes EONS Breast Care Nursing Post
Basic Curriculum as a step towards this end.
Europa Donna welcomesmove to define standardsfor breast care nursing
Ellen Verschuur
Ellen Verschuur, President of Europa Donna
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The specialty of breast care nursing hasdeveloped over the last 20 years in theUK, Australia, US and Scandinavianand Benelux countries, to care for andsupport women and their families affected by breastcancer. Over time, breast care nurses have started tobe employed in a wide range of roles relative totheir education and experience. Role titles that havebeen used include Breast Care Nurse, AdvancedNurse Practitioner,1,2 Nurse Specialist, SpecialistBreast Nurses3,4 and Breast Cancer Nurse5. Theseroles have developed in a variety of settings, oftenexclusive to a single area, including breastscreening, diagnosis, surgery, radiotherapy,metastatic disease and follow up.Evidence from randomised controlled trialssuggests that there are psychological benefits from theintervention of the breast care nurse, includingreduced distress,6 decreased anxiety and depression,and improved physical and social well-being.5-9Studies have also shown significantly reduced levelsof illness-related uncertainty up to six months afterdiagnosis2, significantly lower levels of insomnia anddyspnoea, and alleviation of financial difficulties10.Wherever they are integrated in multidisciplinaryteams, breast care nurses seem to have a positiveimpact on the quality of breast centres. In a randomsample of 72 breast cancer teams, in addition toreducing team workload, the proportion of breastcare nurses correlated positively with overallclinical performance.7Due to the wide variation of nursing practice andeducation across Europe, it cannot be assumed thatnurses working in the field of breast cancer will have
the education or opportunity to be able to work at ahigher level of practice, yet they may wish to bebetter informed about the needs of women withbreast cancer in order to provide optimal care.
INTERNATIONAL GUIDELINESInternational guidelines on standards for the trainingof specialised health professionals dealing withcancer have been recently developed and publishedby EUSOMA (the European Society of Breast CancerSpecialists)8. They state, for example, that breastcare nurses will need an understanding of issuesrelevant to their patients and need to be familiarwith specific knowledge.EUSOMA has also developed internationalguidelines for breast care units whereby breast careclinics throughout Europe can apply foraccreditation. Once an application has beenreceived, a group of specialists, including a surgeon,radiologist, pathologist and breast care nurse, willthen visit the clinic to examine whether it meets thespecified standards.The role of the breast care nurse is seen as animportant part of a breast care unit, and a clinic cannot
Over the past 20 years the role ofbreast care nurses has developed indifferent ways across Europe. The goalof defining a single European categoryof breast cancer nurse is now movingcloser with a new set of trainingstandards set by EUSOMA.
Saskia Claassen
10
breastof the
Defining the role
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obtain accreditation if they have no breast care nurse.As an advanced nurse practitioner in breast cancer,working in the breast clinic of the Catharina hospitalin Eindhoven in the Netherlands, I took part in suchvisits as a member of the EUSOMA team, duringwhich I met with the breast care nurse(s) and thepatient support staff. Our brief included scrutinisingthe provision of information, observing how care isorganised and checking whether the clinic met theEUSOMA criteria.These include, for example, stipulations that thereshould be at least two breast care nurses, who mustbe available to counsel and offer practical advice andemotional support to newly diagnosed patients at thetime the diagnosis is given and be able to furtherexplain treatment plans.Breast care nurses should also be available on
demand from patients in the primary breastcancer follow-up clinic and in the advanced breastcancer clinic.The guidelines also require a breast care nurse tobe present to support women receiving a diagnosis ofadvanced breast cancer.During those visits it became apparent that there isindeed a wide variation of nursing practice andeducation across Europe, and not every country hasformal education for breast care nursing. Some nurseshave training in the hospital, but others gain theirknowledge purely by experience.Though all the visited hospitals had breast carenurses, to comply with the EUSOMA accreditationcriteria, their educational level and role differedgreatly. For example, many still work shifts, whichhas a major impact on their role – if breast carenurses are compelled to do a night shift, they will notbe available to guide patients, have contact with thedoctors or develop patient information.One major step forward has been the decision bythe European Parliamentary Group on Breast Canceras well as EUSOMA to identify breast care nurses ascrucial members of the multidisciplinary team.However, because of the wide variations in the levelof education (if any), there is still a need for EUguidelines on breast care nursing and training.
CURRICULUM FOR CANCER NURSINGEONS has now developed a curriculum to train breastcare nurses that can be used in all Europeancountries, and is set to be launched at the ECCO–ESMO Congress on 20th September. The Breast CareNursing Post Basic Curriculum was developedfollowing the template provided by the broader EONSPost Basic Curriculum in Cancer Nursing 2005 (3rdedn). It remains, however, aimed at a basic level andis intended to be taken as a stand-alone module forworking nurses who are studying part time.The curriculum will be a very important step inenhancing the quality of cancer care in general and,in particular, the quality of care provided by breastcare nurses in all European countries. It lays the basisfor defining a single European category of breast carenurse, who would have the same role in everyhospital, acting as a full member of themultidisciplinary team.This development will contribute to help nursingcare reach a high standard across the whole of Europe.
Details of the references cited in this article can be accessed at
www.cancernurse.eu/communication/eons_newsletter.html
The role of the breast care nurse is seen asan important part of a breast care unit, and aclinic cannot obtain accreditation without one
t care nurse
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Over the last decade, the medicalmanagement of metastatic breastcancer has improved, with the devel-opment of more effective and better-tolerated therapies that can be appliedsequentially to a wider range of patients.1-3Active treatment often allows womenwith metastatic breast cancer, even thosewith visceral disease, to have a prolongedillness trajectory, and for many it maybecome a long-term illness.But the increase in treatment options,together with the potentially prolongedillness trajectory, means that patients arenow faced with a growing number ofdecisions to make, obstacles to overcomeand complex problems to navigate. Andwhile advances in treatment options haveraised expectations for a longer life, thesewomen often have very limited access tothe psychosocial support and information.Not surprisingly, low levels ofprofessional awareness and a failure toacknowledge their needs have beenfound to affect the well-being of womenwith advanced breast cancer.4 Thesefindings are reflected in the experienceof advocacy groups like the UK’s Breast
Cancer Care, which reports thatfeedback from women with metastaticbreast cancer shows they often feelunsupported and isolated.In an effort to address the many andvarious needs of this growing populationof women, in 2006 Breast Cancer Careset up a Secondary Breast CancerTaskforce to improve the care, treatmentand support for people with metastaticbreast cancer.
A PATIENT-LED TASKFORCEThe Taskforce ran for two years as anational coalition of health careprofessionals, charities, policy makersand women with metastatic breast cancer.The agenda was guided by womenliving with metastatic disease. Eightwomen formed a User Advisory Group,which met regularly, and 50 womenparticipated in a Reference Panel,responding to surveys, taking part in focusgroups, commenting on papers, attendingcampaigning events and doing mediainterviews. Two members of the UserGroup were included in the Taskforce.Five priorities were identified through
a process of expert consensus, driven bythe needs outlined in a paper presentedby the User Group, supplemented by theviews and comments from the widerReference Panel. These focused on theneed for better data, access to nursespecialists, information provision,psychological support and shortcomingsat the level of primary care.
COLLECTING THE DATADespite developments in the detectionand management of breast cancer, it isestimated that approximately 50% of allthose with primary operable breastcancer who receive local regionaltreatment alone will havemicrometastases at presentation and willgo on to develop metastatic disease.5 Afurther 5–10% will present withmetastatic disease at diagnosis.6These figures indicate that a significantnumber of the 550,000 women in the UKestimated to be alive with a diagnosis ofbreast cancer will have metastaticdisease.7 However, data on the incidenceof metastatic cancer are not collected inthe UK. The lack of accurate data makes
Many patients diagnosed with metastatic cancer feel
they are not given the level of care and information they
received at the time of their primary diagnosis. A new
policy initiative has started to address these shortcomings.
Five ways we can dobetter for patientswith metastatic disease
Elizabeth Reed and Dora Wheeler
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While advances in treatment options have raised
expectations for a longer life, these women often
have very limited access to the psychosocial
support and information
it difficult for policy makers and serviceproviders to develop services to addressthe needs of these women.The Taskforce therefore drew upa policy document that highlighted theneed to collect data on the incidence ofmetastatic breast cancer. This documentrecommended that data should becollected on the incidence of metastaticbreast cancer and survival, and called onkey stakeholders to address the lack ofdata. This was backed up by a campaign– ‘Stand up and be counted’ – launchedat the UK Parliament in October 2007.In June 2008, the UK’s NationalCancer Intelligence Network announcedthat data on recurrent and metastaticbreast cancer would be collected and
become mandatory for allcancer registries. A good resultfor one priority area of action.
CO-ORDINATING CAREAccess to the appropriatespecialist care was anotherarea identified as a priority.Evidence suggests that thosewith metastatic disease are not receivingthe same levels of attention and care asthose with primary disease.8This may explain why uncontrolledsymptoms such as fatigue, pain,
A meeting of the User Advisory Group,
which guided the work of the
Secondary Breast Cancer Taskforce
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sleeplessness and depression havebeen found to be a problem in thisgroup of women.8-10Many women on the Taskforce felttheir experience of being diagnosedwith metastatic breast cancer comparedunfavourably to the experience theyhad on being diagnosed with primarybreast cancer, when they had feltinformed and supported.Few of them had been offered breastcare nursing support at the time theywere informed that their disease had
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spread, and many felt they were left tonavigate their way through the complexhealth and social care services with littleformal support.This may be related to the findings ofa 2007 survey of UK breast care nurses,which found that their time is primarilydedicated to meeting the needs ofwomen in the adjuvant setting. Indeedsome felt they had neither theknowledge nor the confidence to care forwomen with metastatic disease.11The Taskforce therefore called foreveryone with a diagnosis of metastaticbreast cancer to have a key worker withthe appropriate skills and knowledge tosupport and care for women withmetastatic breast cancer. Breast CancerCare is currently collating informationfrom around the UK about the models ofcare that could be applied to this patientgroup and is planning research toinvestigate the impact of differentfollow-up models.
APPROPRIATE INFORMATIONLack of appropriate information wasanother key issue identified by theTaskforce. Research has shown that whenpatients are diagnosed with recurrentcancer, treatment staff tend to assume thatthe experience of their initial diagnosiswould have prepared them for therecurrence. Ninety per cent of patientssaid they had been given less attentionand information and that staff simply
assumed that they were coping and hadsufficient support.12 A separate studyfound that professionals’ engagement withmetastatic breast cancer patients appearsto wane as the disease progresses and thetreatment options dwindle.13In response to this evidence andfeedback from the User Group and theReference Panel, the Taskforcerecommended that all people withmetastatic breast cancer have theirinformation needs formally assessed.Breast Cancer Care, in consultation withwomen with metastatic breast cancer
and health care professionals, hasproduced a pack that includesinformation on diagnosis and treatmentalong with other resources. It is designedto function as a personal record for eachwoman. It is free and available toanyone through their health careprofessional or Breast Cancer Care’swebsite (www.breastcancercare.org.uk).
PSYCHOLOGICAL SUPPORTThe Taskforce felt strongly that womenwith metastatic breast cancer shouldhave their psychological needs assessedon a regular basis, and identified this asanother priority area.Given that up to 50% of women withmetastatic breast cancer experienceclinically significant levels of traumaticstress symptoms associated with theircancer,14 and one-third of women withadvanced breast cancer have been foundto have an affective disorder – sufficientlysevere and persistent to require anappropriate intervention in one in threeof them10 – the need to address thepsychological health of this group ofpatients is of paramount importance.The needs of family and friends werealso a concern for the women in theUser Group and Reference Panel. They
The Secondary Breast Cancer Taskforce drew up the following
recommendations for action, based on the priorities identified by the User
Advisory Group, together with comments from the Reference Panel.
 Data should be collected on the incidence and survival of patients with
metastatic breast cancer
 Every patient should be given a key worker who has the appropriate
knowledge to support and care for women with metastatic breast cancer
 Formal assessment should be made of the information needs of each
patient
 Consideration should be given to assessing psychological well-being, using
validated assessment tools, for both the patient and family members
 Management of women with metastatic breast cancer at the primary care
level should be improved
To find out more about the Taskforce’s achievements and further work, please
go to http://www.breastcancercare.org.uk/server/show/nav.728
Recommendations of the Taskforce
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Mike Richards, the UK National
Cancer Director, speaking at
the launch of the final report of
the Secondary Breast Cancer
Taskforce, November 2008
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international research. However, theTaskforce found little evidence to showthat this translates into assessment ofneeds in clinical practice in the UK. Noris it reflected in the level of provision ofservices offering ongoing support. Thedevelopment of support servicesappears to lag behind the developmentof life-prolonging treatment.The Taskforce came to an end inNovember 2008, but its work continues.Breast Cancer Care continues toinfluence and improve the care of thosewith metastatic breast cancer in all ofthe areas identified, throughcollaboration with governmentinitiatives such as the NationalCancer Survivorship Initiative andcampaigning work.
Details of the references cited in this article can
be accessed at www.cancernurse.eu/
communication/eons_newsletter.html
with their GP before being referred to abreast cancer specialist.18Women in the User Group and theReference Panel said they felt that theirGPs were not up to date with themedical management of metastaticbreast cancer, and the communicationbetween primary and hospital carewas fragmented.In consultation with users andprimary care clinicians, the Taskforcetherefore developed a tool to supportprimary health care teams in themanagement of women with metastaticbreast cancer,19 and recommends eachGP is sent a copy at the time they aresent a letter confirming a patient’smetastatic diagnosis.
FROM RESEARCH TO PRACTICEThe multidimensional needs of patientswith metastatic breast cancer have beenhighlighted by a significant body of
Health care professionals appear to underestimate the support
needed by those with metastatic cancer, and this unmet need is
associated with high levels of burden on the caregiver, including
poor health
15
felt health care professionals failed toacknowledge these needs.Their experience is supported byevidence which suggests that health careprofessionals appear to underestimatethe support needed by those withmetastatic cancer, and this unmet needis associated with high levels of burdenon the caregiver, including poor health.15Those caring for people with metastaticbreast cancer can have similar levels ofdepression to those they care for.16The Taskforce therefore called forinitiatives on the part of government toconsider the assessment of psychologicalwell-being, using validated assessmenttools for both the patient and familymembers, at key points – such as diseaseprogression – and regularly throughouttheir illness trajectory.
BETTER PRIMARY CAREPrimary care services have animportant role to play in the care ofpatients with metastatic breast cancer.But the Taskforce found many primarycare providers have poor levels ofawareness and are ill-equipped to fufilthis role. Addressing this shortcomingwas identified as the fifth priorityarea for action.The Taskforce identified three mainconcerns:
 Poor awareness among generalpractitioners (GPs) of the signs andsymptoms of metastatic breast cancer
 Inadequate knowledge aboutmanaging metastatic breast canceramong primary care clinicians
 A lack of communication betweenprimary and hospital care providers.These concerns are mirrored by researchwhich has found that the involvement ofGPs and palliative care services in themanagement of metastatic breast canceris limited, with care providedpredominantly through outpatientclinics by hospital specialists, with littleor no community-based support.17A survey undertaken by the Taskforcefound that 64% of women presentedtheir symptoms to their GP first, and66% had more than one appointment
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Adjuvant endocrine treatment (AET) is usedto reduce the risk of recurrence in womenwith hormone-responsive breast cancer.Women generally remain on AET for five years,and emerging evidence now suggests that itmay be beneficial to extend the treatmentduration even further.Failure to take the medication asprescribed is known to jeopardise theefficacy of the treatment. However,adherence to medication cannot beassumed, even in the face of a potentiallylife-threatening disease such as breast cancer.1Finding ways to help women stick with theirprescribed therapy is becomingincreasingly important, and cancernurses have a valuable role to play.
SHARED DECISION-MAKINGResearch into adherence has consistentlyhighlighted the importance of the waytreatment decisions are made. Shareddecision-making has been suggested to be thepatients’ preferred approach and to have apositive impact on outcome.2,3 But as treatmentoptions for breast cancer become ever morenumerous and complex, with varying types ofside-effects, women are finding it increasinglydifficult to weigh up their relative advantagesand disadvantages.
Boosting adherence to
adjuvant endocrine therapy
Yvonne Wengström and Eva Gustafsson
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Five years can be a long time to keep taking a medication, particularly if you arebothered by side-effects, can feel no benefit, and don’t understand why yourdoctor has recommended it. Nurses are well placed to help address some ofthese problems and can help women stick with their prescribed therapy.
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Recent research looking at predictors of adherence totamoxifen in breast cancer patients has demonstrated anassociation between long-term adherence and the rightamount of involvement in decision-making and patient-centred care.4This research suggests that non-adherence totreatment is the result of three factors;
 lack of information about the advantages anddisadvantages
 lack of visible benefits
 need for psychological adaptation in order to realisethe necessity for treatment.
COMMUNICATING AT THE RIGHT LEVELThe decision-making process needs to include healthcare professionals working with patients to ensurethat they have the information they need to makedifficult decisions.An understanding of the patient’s choice of degreeof partnership is also essential in patient-centred care.It is important to communicate information aboutdifferent treatment options and their advantagesand disadvantages, due to the complexity of theside-effects of different therapies. Thetreatment choices are complicated forthese women, as they are mainly in theform of recommendations rather thanclear-cut options.Doctors have been found tounderestimate the need for thisinformation, and the trend in recentyears is that patients with a cancerwant more counselling, informationand influence over treatment.5,6Perceived control over illness alsohas an influence on adherence tomedication.7 Socio-demographicfactors such as gender, level ofeducation and race have not beenfound to influence adherence;however, some research suggests thatnon-adherence to AET is more likelyat a more advanced age4 and thatadherence to long-term medication oftendeclines over time.3 It is also a well-known factthat patients are less likely to adhere to complextherapies or those with adverse side-effects.1,4-9
COMMUNICATING ABOUT SIDE-EFFECTSThe benefits of AET are well documented and it isoften well-tolerated; however, its many side-effects havenot been sufficiently recognised. Symptoms and side-effects are often related to menopausal symptoms,
which can have a severe impact on quality of life,although women who have had previous treatment withchemotherapy may describe the side-effects of AET asless severe.Information concerning side-effects is oftenperceived as unsystematic, and many think that theinformation leaflet in the medication box isfrightening. Although patients are often willing totolerate side-effects when faced with a life-threateningillness such as breast cancer, it cannot be assumed thatthey will actually adhere to medication, and there isresearch evidence to show that unpleasant side-effectsof medication may impede adherence.4,5Our clinical experience indicates that sometimes theside-effects may be diminished by adjusting the time ofday at which the pill is taken. This is supported by afinding that women who take tamoxifen may have adifferent diurnal pattern of flushing than those who arenot taking tamoxifen.10 Complementary therapies, suchas acupuncture, may also be helpful.
COMMUNICATING ABOUT BENEFITS AND RISKSIt seems obvious that it is important to know whyAET is recommended, along with information aboutthe benefits and risks of the treatment. However, it isnot uncommon for women to lack this informationand to have a poor understanding of the purpose andpreventative aim of AET.Research shows that adherence requires that patientsunderstand their illness and the need for themedications prescribed.11 Information about risks andbenefits influences adherence and enables patients tomake an informed choice. Belief in the necessity oftaking a prescribed medicine is an important factor inadherence; there is evidence that those who adhere totreatment experience benefits whereas non-adherers aremore likely to report no benefit.12If we are to achieve optimal adherence, effectivecommunication between patients and health careprofessionals is essential. This may well be a challengein the adjuvant situation if the need for, or benefit of,the AET is not clear to the patient.Some factors and experiences have been identifiedthat will have an impact on whether treatment will becontinued or not. Nurses in cancer care are in a centralposition to support patients and hence need to developbetter strategies to educate women with breast cancerabout treatment choices, in order to help them tofunction better in their preferred decision role and toenhance adherence to long-term adjuvant treatment.
Details of the references cited in this article can be accessed at
www.cancernurse.eu/communication/eons_newsletter.html
Complianceor adherence?
The increase in patient
autonomy has led to
the term ‘adherence’
replacing the more
authority-laden
term ‘compliance’
in the literature.
‘Compliance’ implies
an imbalance in the
doctor–patient
relationship: the
patient must do as
they are told.
‘Adherence’, in con-
trast, can be defined
as “the extent to which
a person’s behaviour
coincides with medical
or health advice”. This
highlights the impor-
tance of ensuring
women are confident
they have the informa-
tion they need about
risks, benefits and
side-effects and
they understand
why the medical
advice is important.
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The outcome of cancer treatment,in terms of survival and quality oflife, is known to vary significantly not justbetween countries, but within countries.Outcomes may be better in some geograph-ical regions than others. Certain socio-eco-nomic groups may do worse than others.In the UK it is clear that there are in-equalities in cancer outcomes experi-
enced by a range of different groups, in-cluding those from black and minorityethnic groups and older people.Enhancing the quality and experienceof care for these groups was prioritised asa key aim of the Department of Health’s2007 Cancer Reform Strategy. Equitableprovision of information and support isseen as fundamental to meeting this aim.1
With this in mind, the UK charity BreastCancer Care, in collaboration with King’sCollege London, set out to explore thebarriers to the uptake of Breast CancerCare’s services, and develop a strategy forenhancing uptake of services by peopleaffected by breast cancer.The Better Access Better Services(BABS) project had a specific remit to
A one-size-fits-all strategy
for providing information
and support to breast
cancer patients is
bound to leave certain
groups with unmet
needs.The Better Access
Better Services project,
which focused on
reaching older women,
and those from black
and minority ethnic
groups, recommends a
more tailored and
flexible approach.
Emma Blows, Karen Scanlon, Alison Richardson and Emma Ream
How to engage withhard-to-reach groups in the UK
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explore barriers experienced by ‘hard-to-reach’ groups, including black andminority ethnic groups, and older women(aged 65 years or more).As a first step, a comprehensive reviewof the literature was carried out to explorehow breast cancer patients from thesehard-to-reach groups differed from thosein the general population in terms of theirinformation needs, the sources ofinformation available to them, and theway they go about seeking information.2
A COMPLEX PICTUREThe review demonstrated that, consistentwith the generic cancer literature, theinformation needs of women with breastcancer are highly individualistic andchange as women move though the breastcancer journey.3,4The breast care nurse was identifiedas a valuable source of information forwomen with breast cancer.3 In particular,nurses promote continuity in care,acting as a link between patients andother health care professionals in thebreast cancer team.However, access to health careprofessionals is increasingly difficult inthe period following active treatment. Asa result, women’s needs are typically notmet at this time.3,5 They therefore seekalternative sources of information to meettheir needs.6For example, the experiences andadvice of other patients are a valuablesource of information to women withbreast cancer, as these women can tellpatients things that healthcareprofessionals may not know, or do notthink to pass on.7Information seeking behaviours arehighly individualistic, and the functionsof information also fluctuate over time.8Women may seek information tomaintain a sense of control at anuncertain time, reduce anxiety, facilitatecoping, and increase understanding oftreatments to enable them to engage indecision-making.8,9 Equally, women mayavoid information to preventworry and avoid negative feelings abouttheir illness.8
HARD-TO-REACH GROUPSCompared to women from the generalpopulation, women from black and ethnicminority groups tend to have morelimited knowledge of breast cancer.Women from some communitiesbelieve that breast cancer is a ‘whitewoman’s disease’ and thus perceivethemselves to be at a low risk ofdeveloping the disease.10Cultural and health beliefs, and fearsabout breast cancer, prevent women fromseeking advice and treatment.10Women from black and ethnic minoritygroups have many similar informationneeds to the general population.11However, their access to culturallyappropriate written and verbal sources tomeet those needs is very limited.10When it comes to the needs andbehaviour of older women, the literaturesuggests that they prefer their informationto come from the hospital specialist and,in contrast to younger women, they tendnot to seek alternative sources ofinformation.5,12They place faith in health careprofessionals, adopting a ‘doctor knowsbest’ approach and, on the whole, take apassive role in decision-making andmanagement of their illness.13However, there is concern that thequality of communication andinteraction between older women andhealth care professionals declines withage. In particular, studies have foundthat specialists often spend less time inconsultations with patients the olderthey are.14This may contribute to older womennot receiving appropriate levels ofinformation and support.
ACCESSIBILITY OF SERVICESHow well do the services provided forwomen with breast cancer by UK statutoryand voluntary sectors fit the needs of olderwomen and those from black and ethnicminority communities? To answer thisquestion, focus groups were held withAsian and African Caribbean women, andsemi-structured telephone interviews wereconducted with older women, in order toexplore their information and supportneeds, to find out what role, if any, wasplayed by voluntary organisations inmeeting their needs and to try to identifybarriers and facilitators influencing uptakeof services provided by the statutory andvoluntary sectors.
Lack of relevanceBoth Asian and African Caribbean womenhad unmet information and supportneeds, particularly relating to skin andhair care, and dietary concerns.Breast care nurses were considered animportant source of information andsupport, but were inconsistent insignposting to services appropriate to theneeds of women from these communities.However, women also felt servicesprovided by both the statutory andvoluntary sectors were often not relevantto, or representative of, their needs. As aresult, women from Asian and AfricanCaribbean communities were oftendissatisfied with services used.
Poor communicationHealth care professionals were the mostimportant source of information andsupport for the older women in this study.However, many experienced poorcommunication, and a lack of
Breast care nurses were considered an important
source of information and support, but were inconsistent
in signposting to services appropriate to the needs of
women from these communities
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The BABS project documented a
wide variety of experiences and
views among older women and
those from black and minority
ethnic communities, a selection of
which are presented below.
“The nurse should sit down with you,
tell you certain things and make a
connection, they know who you are
and what you’re all about.”
“Lady, do not direct me upstairs
because the wigs you’ve got
up there do not cater for a
Black woman.”
“I had a breast cancer nurse
and she gave me information
and ... kept in touch with me.
Not as much as perhaps... she
was a very busy lady…”
“[I] received very short shrift. She
seemed to think I was a stupid old
woman who was making a fuss
about nothing…”
“I didn’t know what I needed to
know, I didn’t know what help I
needed to have or what I was
entitled to or whatever… you don’t
know what’s out there.”
“Issues relating to skin that are quite
apart from Caucasian women –
that is the level of information I
wanted to hear but you don’t get it.”
WHAT THEY SAID
20
involvement in decision-making regardingtreatment and care.There seemed to be great variabilityin the level of support provided byhealth care professionals, particularlyafter treatment ended. Some womenreported that they had felt ‘cast adrift’and had been apprehensive about lifeafter treatment.However, others felt reassured,trusted the information provided andfelt health care professionals werelooking after them. Particular importance was placed on therole of consultants and breast care nurses,who clearly play a crucial role inproviding information and support tothese women.
HOW BREAST CARE NURSES CAN HELPThe Better Access Better Services projectused a variety of research and evaluationtechniques to obtain a comprehensivepicture of the information and supportneeds of breast cancer patients, in partic-ular among older women and those fromblack and minority ethnic communities.The findings repeatedly highlighted theimportant role played by breast care nursesin providing information and support towomen from hard-to-reach groups.However, it is clear that much moreneeds to be done if older women andthose from black and ethnic minoritycommunities are to receive theinformation and support services thatthey need, and if progress is to be made inreducing disparities in the outcomes ofcancer treatment.The BABS project made a number ofspecific recommendations coveringindividual assessment of information andsupport needs, improving access tospecialist nurses, training incommunication and better signposting toculturally appropriate services.
Assessment of needsBreast care nurses should continue to beaware of the changing needs and prefer-ences of individuals. The type and timingof information giving should be continu-ally assessed, to ensure each patient re-ceives information support specific totheir individual needs.
Specialist nursesBreast care nurses play a pivotal role inthe provision of information. Greater pro-vision should be made for the hiring andtraining of specialist breast care nursesand/or cancer-specific information special-ists, who can devote their time and expert-ise to providing each patient with theinformation they require.
Communication skills trainingHealth care professionals need to be re-sponsive and adaptable to patient infor-mation and support needs. This isespecially important when consulting pa-tients from black and minority ethnicgroups and older women.Some health care professionals mayneed training in cultural awareness anddiversity issues. Specific training oncommunicating with older women shouldalso be considered, to ensure they areencouraged to engage in the decision-making process, if they wish.
SignpostingThe development and delivery of servicesthat are culturally appropriate to patientsfrom a diverse range of backgrounds isimportant. Women from different blackand minority ethnic communities anddifferent age groups have specificconcerns that should be considered, andcannot be addressed with a ‘one-size fitsall’ approach to service delivery.In addition, better signposting by breastcare nurses to culturally appropriate statutoryand voluntary support services is needed.
Details of the references cited in this article can be
accessed at www.cancernurse.eu/
communication/eons_newsletter.html
Women from different black and minority ethnic communities
and different age groups have specific concerns that
should be considered, and cannot be addressed with a
‘one-size fits all’ approach to service delivery
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Therecent rapid development oftreatment modalities has changedperceptions of breast cancer. Breastcancer is now understood to be aheterogeneous, highly variable disease, requiringindividualised treatment.More than 80% of breast cancer patients survivetheir disease and are confronted with the challengesof cancer survivorship. Due to its long-lasting natureand risk of recurrence, breast cancer should beconsidered a chronic disease. Women diagnosed withbreast cancer develop specific emotional,informational and physical needs that have beenanalysed in oncology nursing over the last decade.Many of these studies conclude that, while expressinga general satisfaction with the care provided, manywomen also report a number of unmet supportivecare needs, especially in later phases of treatment andduring survivorship.
The WHO report “Preparing a health care workforcefor the 21st century: the challenge of chronicconditions”1 criticises current models of care foremphasising diagnosis and treatment of acutediseases. Such outdated models of care, it argues, areinadequate for a growing population of patients withhealth problems that persist over decades or even alifetime. Patients are forced to consult multiple healthcare providers who lack coordination amongthemselves and across settings, resulting in care beingexpensive, confusing, or even harmful to patients.2In this report the WHO defines five basiccompetencies needed when caring for patientswith chronic conditions: patient-centred care,partnering, quality improvement, informationand communication technology and a publichealth perspective.
The World Health Organizationhas identified new models andpractices of care appropriate forthe rising number of patientswith chronic conditions. Withthe emphasis on patient-centred care and partnering,well-trained breast carenurses will be perfectlyplaced to play a central role.
The breast care nurse
a 21st century concept
Manuela Eicher
21
Da
vi
d
To
w
ne
nd
/R
oy
al
M
ar
sd
en
Pages_21-23.OK.qxp:Layout 1  8/9/09  15:14  Page 21
22
changes of models of care. They can therefore beconsidered as key players to promote a shift fromacute care towards models of care in chronicconditions for people affected by breast cancer.
PATIENT-CENTRED CAREThe WHO suggests a shift from health professional-centred care towards patient-centred care. Theessence of patient-centred care is an understanding ofthe illness experience from the patient’s perspective.Central elements in such a shift include:
 being responsive to and respectful of the needs,values, differences, and preferences of the patient
 aiming at coordinating continuous and timely care
 relieving pain and emotional suffering
 listening and communicating
 providing education and information
 sharing decision making and management
 preventing disease, disabilities, and impairments
 promoting wellness and healthy behaviour.
The EONS Breast Care Nursing Post Basic Curriculumrequires BCNs to identify, validate and prioritisepotential and actual physical, psychological, social,sexual and spiritual health, coping strategies andconsequent support needs of people affected by breastcancer across the continuum of care.They should demonstrate an ability to integratecontemporary knowledge and evidence about breastcancer and its impact, to effectively promote self-management strategies and provide a range ofsupportive care interventions to meet the multiplehealth needs of people with breast cancer, in thecontext of a multidisciplinary approach to care.BCNs should also be able to provide education toenable patients and their significant others to achieveoptimal self-management strategies, and informationto assist them to achieve optimal health outcomes,reduce distress and make informed decisions abouttreatment options and support available within thecommunity. When fully implemented, the EONScurriculum puts BCNs in a promising position torealise the WHO’s plea for more patient-centred care.
PartneringThe WHO defines partnering as the ability to joinwith patients, other providers and communities foreffective care of patients with chronic conditions.The workforce need skills that allow them to sharepower and involve patients in all aspects ofdecision-making in their health care. They need theability to work in teams and collaborate with otherproviders: those who care for the patient across
BREAST CANCER PATIENTSThe particular needs of women with breast cancer,the heterogeneity of this chronic disease, as well asthe development of diagnostic and treatmentmodalities, have led to the development ofmultidisciplinary teams. Such teams tend to improveconsistency, continuity, coordination and costeffectiveness of care by coordinating a team ofspecialists in this particular field.3Since 2000 the European Society of Breast CancerSpecialists (EUSOMA) has required breast care nurses(BCNs) to be part of these teams.4 Whereas in somecountries (such as the UK, the Netherlands, theScandinavian countries) BCNs are an integral part ofspecialist breast units, other countries (such as France)tend to continue traditional models of care, withoutoffering BCN services. To date, all over Europe, thecompetencies, roles and training of BCNs varyconsiderably between different settings and countries.5
TOWARDS A CONSISTENT MODEL OF
BREAST CARE NURSINGIn the future, BCNs should have more consistentroles, competencies and training. This would enablepatients to better understand what needs could beaddressed to BCNs. One particular benefit could be astandardised patient-centred, cooperative approachincluding an overall improvement of coordinationamong health care providers and settings. This wouldenable nursing science to better analyse the efficacyand cost-effectiveness of BCNs.With their particular role within multidisciplinaryteams, BCNs are well positioned to take on aprominent position for the implementation of newmodels of care in breast cancer care all over Europe.To see why, you only have to examine the similaritiesbetween two of the basic competencies defined by theWHO (patient-centred care and partnering) and thecompetencies for BCNs specified in EONS BreastCare Nursing Post Basic Curriculum.Being equipped with these particular competencies,BCNs can make major contributions to the required
When fully implemented, the EONScurriculum puts breast care nurses ina promising position to realise the WHO’splea for more patient-centred care
Competencies
The WHO defines
competencies as the
skills, abilities, knowl-
edge, behaviours and
attitudes that are
instrumental in the
delivery of desired
results and,
consequently, of job
performance. Patient-
centred care and
partnering are two
of the five core
competencies identi-
fied as key for the
delivery of care for
patients with chronic
conditions in the WHO
publication “Preparing
a health care
workforce for the
21st century.” Both
competencies are
central components
of the EONS Breast
Care Nursing Post
Basic Curriculum.
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time, in different settings, from different disciplines,and for different diseases that might coexist in thesame patient.According to the EONS curriculum, BCNs shoulddevelop collaborative therapeutic relationships withpeople affected by cancer and their significantothers to anticipate and meet their multiple careneeds across the continuum of breast cancer care.They should be aware of the variety of health careresources relevant to the needs of clients withbreast cancer and utilise them appropriately. Theyare responsible for facilitating a coordinated andefficient approach to the delivery of health andsupport services and care interventions that areresponsive to individual clinical and socialcircumstances across the continuum of breastcancer care.Furthermore BCN’s should be able to collaboratewith the person receiving care, their significantothers, other nurses and members of the health care
team, to optimise health outcomes for people withbreast cancer. Equally here, the EONS curriculumenables BCNs to take a leading role in realising theWHO’s plea for partnering within and beyond amultidisciplinary team and its institutional context.Taken as a whole, BCNs trained and acting inaccordance with the competencies defined in theEONS curriculum are well positioned to realise thecore competencies the WHO has identified asessential for health care providers in the 21stcentury. They can and should be key players in themuch-needed shift from acute to more chronicoriented models and practices of care across Europe.Enabling BCNs to play this role will require moreconsistency in the training of BCNs and in the extentto which they are able to play a full and integratedrole within multidisciplinary breast care teams.
Details of the references cited in this article can be accessed at
www.cancernurse.eu/communication/eons_newsletter.html
Functioning as a
fully integrated
member of a
multidisciplinary
breast care team,
such as this one at
the European
Institute of Oncology
in Milan, is essential
to the partnering
role of the breast
care nurse
Pages_21-23.OK.qxp:Layout 1  8/9/09  15:14  Page 23
24
The receptors that indicate treat-ment and prognosis of breast can-cer have become well known to publicand health care professionals alike,although the implications of diagnosis arenot always clear to the patient (“Thankheavens I’m HER2 positive and I can haveHerceptin”). These subtypes are becomingmore distinct, if more complicated.Oestrogen receptor (ER), progesteronereceptor (PR), and human epidermalgrowth factor receptor 2 (HER2) havebecome well-known terms in thecommon parlance in breast cancer care.The combination of the presence(positive) or absence (negative) ofreceptors is an indicator of the diseaseresponse to treatment. One receptoralone is not sufficient to make atreatment decision and, as a result,subtypes are classified according to thecombination of receptors, giving rise tonew terms such as the relatively newtriple negative phenotype (TNP) cancer,which is ER negative, PR negative andHER negative. This subtype is furtherdistinguished by whether it also hasover-expression of the basal markersCK5/6 and epidermal growth factorreceptors (EGFR), so that within the TNPsubtype there is further classification:those TNP in the majority with the
The treatment of breast cancer is increasingly dictated by the status of receptors. The relativelynew triple negative phenotype – negative for ER, PR and HER2 – has a particularly poorprognosisis, and the search is on to find the most effective therapy options.
The triple negative phenotype
what is it and how do we treat it?
Kay Townsend
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markers – the ‘basal-like’ TNP –and those without the markers –the ‘non-basal-like’ or ‘normalbreast-like’ TNP. 1Unfortunately it is not quite asclear-cut as the table belowsuggests, because some cancersthat are basal do not appear to beTNP cancers. The debate betweenresearchers continues as methodsof distinguishing between thebasal cancers and the TNP ‘basal-like’ cancers develop.2 For now,the treatment decisions should bebased upon the receptor status ofthe cancer, and with those thathave the triple negative result,chemotherapy is recognised as thefirst line of treatment.3It is known that patients with anER-negative status gain greater benefitfrom intensive chemotherapies thanthose with an ER-positive status,4 butTNP is a relatively new subtype, and theideal approach is far from certain.Studies have shown a predominance ofthe BRCA1 mutation in these cancers,which is sensitive to both cross-linkingagents (e.g. platinum salts) and the polyADP-ribose polymerase (PARP) enzyme
25
inhibitor.5 Trials (TNT trial, BRCA trial)are currently recruiting to see if thiscan be taken advantage of. The keypoints, however, remain that thissubtype of breast cancer needs research,that the systemic therapy option ischemotherapy and that phase III trialsare currently recruiting.Future treatments may involvemonoclonal antibodies such asbevacizumab. This antibody affects thegrowth of tumour blood vessels by
targeting the vascular endothelial growthfactor (VEGF) to inhibit its action. Althoughit is hoped that affecting angiogenesis inthese TNP cancers will be successful, theUK National Institute of Health andClinical Excellence (NICE) has suspendedthe technology appraisal of its use in first-line treatment of metastatic breast cancerwith paclitaxel, acting on manufacturer’sadvice that it is unlikely to be cost-effectivewhen compared with paclitaxel alone.6A further technology appraisal ofbevacizumab with non-taxane chemotherapyis planned.This relatively newsubtype of breast cancerhas poor prognosis, asthe treatment optionsare limited at this time.Systemic therapy optionis chemotherapy, andresearch for the idealregimen is beinginvestigated withtrials that arecurrently recruiting.
Details of the references
cited in this article can
be accessed at
www.cancernurse.eu/
communication/
eons_newsletter.html
Breast cancers testing
negative for oestrogen,
progesterone and HER2
receptors (triple negative)
are now further classified into
‘basal-like’ and ‘non-basal-
like’ subtypes. The
implications of the latter
subtyping for treatment are
not yet clear
IHC immunohistochemistry, FISH,
fluorescent in situ hybridisation
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SUBTYPE
breast cancer
ER+
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HER2 -
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“NON-BASAL”
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ER - HER2 +
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ER-
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responsive
Associated with
increasing age
Luminal A
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More frequently
ER+/PR-
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highly aggressive
subtype
High-grade histology
Risk increased in
younger age (<40)
Outcome improved
with HER2
HER2 ER- HER2+
Aggressive subtype
High-grade histology,
high rate
Risk increased in
younger age <40
‘Basal-like’ TNP
Similar to basal-like
Better prognosis
than basal-like triple
negative
‘Non-basal’ TNP
What subtypes tell us about a breast cancer
Source: This table and the graphic above were adapted from Lyman et al (2008)7
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Breast care nursing first began asa specialty in the early 1980s.Some of the first descriptions of its roleand importance in supporting andcounselling women with breast canceroriginated in the UK.1-4 Maguire and hiscolleagues1 emphasised the importanceof monitoring the psychosocial well-being of women with breast cancer, andthe role of the nurse counsellor in pro-viding such a service.Later, during the 1990s, these reportsstarted to make an impact in other coun-tries such as the US, Australia, Scandi-navia and Israel. 5-8In Israel, for instance, breast care nurs-ing began its development as a recognisedspecialty in 1996, thanks to the generoussupport of the Israel Cancer Association.The position was established first at theHadassah Medical Organisation inJerusalem. Since then, most clinics in thecountry have followed suit, providing anurse (some have two) dedicated to thecare of women with breast cancer. Todaythere are around 25 breast care nurses em-ployed across the country.However, the role carried out by thesespecialist nurses working in various West-ern countries lacks standardised practice,
and most importantly a uniform standardof curriculum.As stated byAmir et al,9who explored therole of the breast care nurse (BCNs) in theUK, “…there is evidence that the BCN prac-tices in advanced level of practice. However,there is a severe lack of evidence-based de-scription of that advanced practice.”
UNEVEN EDUCATIONThe training of breast care nurses remainsvariable and falls short of agreed stan-dards of education for the profession in anumber of ways.
 Different types of qualification. Somenurses may have a diploma, others afirst degree or a postgraduateacademic grade in nursing.
 Different levels of training inoncology nursing in general, and inbreast care nursing in particular.Some nurses may have taken up post-basic oncology training and educationas well as a special training in nursingpatients with breast cancer. Othersmay not.
 Different professional backgroundand skills. Some nurses may chose tobecome a breast care nurse afterspending many years working in
oncology, surgery or plastic surgery,and some have a long experience innursing women with breast cancer,whereas others may come from atotally different working background,and with little experience in this area.
 Different personal experience, inparticular with breast cancer. This isof great importance and may have a
Breast care nurses play an increasingly central role in the
care of women with breast cancer. Their qualifications,
however, vary widely across Europe, and their training lacks
uniformity and common minimum standards.
Training and education
setting the standards for the next generation
Ilana Kadmon
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major influence on the work of thenurse. Some of nurses haveexperienced breast cancer themselves(or had a very close family memberwith the disease) and consequentlytheir outlook on and approach to thedisease and its treatment may be verydifferent from those who did notconfront the disease on a personal level.
 Diverse national, cultural andpolitical variations in the status ofnursing and nursing practice andeducation. In some countries, nursingis well recognised as an academicprofession with various specialties,while in others it is not established atall, and nurses receive no formaleducation. This may obviously createa large diversity in the educationallevel of this sub-profession.
APPROPRIATE STANDARD
OF TRAININGMany studies – mainly originating fromAustralia – have examined the impor-tance of the role of the breast cancernurse to women diagnosed with cancer.However, no research, to date, has exam-ined the education of these nurses and itsinfluence on the standard of care.In the UK and Australia, there are arange of structured courses for the train-ing of nurses in the area of breast cancer.The Royal College of Nursing, the profes-sional body representing nurses in theUK, has developed various modules ofeducation for breast care nursing.Writing about the developing role ofthe nurse specialist in breast care inBritain, Burnet et al10 say that: “They[the RCN] have identified three stagesin breast care nurse's career develop-ment: breast care nurse, clinical nursespecialist and nurse consultant. Theyrecommended a structured educationalpreparation, including specific qualifica-tions in breast care nursing, teaching, as-sessing and counselling, as well as ahigher level degree.”However, apart from the British andthe Australian experience, no national orrecognised curriculum exists for this spe-
cialist training, nor is there any recog-nised European training to provide astandard in this area of care.Moreover, when searching the litera-ture, no article was found that addressedthe issue of the special education neededfor breast care nurses.Given the lack of standards, it is im-portant to set minimum educational andbackground competencies that the nurseshould have prior to enrolling in an edu-cational and training course to become abreast care nurse. These should include:
 At least a first degree in nursing,preferably a Masters
 Post-basic education in cancer nursing
 Professional experience working for afew years with cancer, and preferablybreast cancer patients
 Some form of experience in nursingresearch.It should be emphasised that manynurses throughout Europe do not havethe right educational background to beemployed in such an occupation. Thesenurses started their job either throughtheir own initiative, or thanks to the en-treprising efforts of nursing management,or the goodwill of a doctor working withwomen with breast cancer.These nurses may be referred to as thefirst generation of breast care nurses. It re-mains our challenge and responsibility tothink about the future and the next gener-ation of breast care nurses in Europe, andto ensure that they receive the appropriatestandard of training, with a strong back-ground experience before taking up thismost important and exciting occupation.
Details of the references cited in this article can
be accessed at www.cancernurse.eu/
communication/eons_newsletter.html
Hilary Noonan and Fiona Brady
receive a TITAN dissemination award
for their project ''Febrile neutropenia
and Shared Care''
No national or recognised curriculum exists for this
specialist training, nor is there any recognised European
training to provide a standard in this area of care
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Minimising the
risk of lymphoedema
early information is key
Lymphoedema affects one-thirdof women whose treatment forbreast cancer involved lymphnode intervention. Thecondition can be kept toa minimum if timely,balanced and preciseinformation and advice,tailored to individualcircumstances,are given at theright time.
28
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Lymphoedema can develop atany time following breast cancertreatment and women carry a life-longrisk of its development.It is estimated that one-third ofwomen will develop lymphoedema atsome time following treatment forbreast cancer.1As women undergo treatment forbreast cancer, they come into contactwith many health care professionals, allof whom can play an important part ineducation about lymphoedema.It is at this time that informationabout the risk of lymphoedema shouldbe provided, along with adviceconcerning care of the ‘at risk’ arm.If information is provided at thisearly stage, women can be encouraged toadopt healthy activities that promotelymph drainage, so minimising therisk of lymphoedema developing inthe future.Knowledge of which women are atrisk, why they are at risk and whatcan be done to minimise the risk istherefore essential.
THE ROOT OF THE PROBLEMFollowing breast cancer treatment,lymphoedema can develop in all or partof a limb, and is termed secondarylymphoedema because it arises as aresult of disruption or obliteration oflymph vessels at the time of surgery, orduring radiotherapy. As drainage routesfor the lymph reduce, lymphatic fluidcan accumulate in the tissues giving theappearance of swelling.It is usually the woman who firstdiscovers the swelling, which mayinitially be mild and uncomplicated.However, if left untreated, it canprogress to become severe andeventually lead to skin and tissuescomplications.Swelling can also develop within thebreast tissue following breast conservingtreatment. Among women with largerbreasts and those who have had acombination of surgery andradiotherapy,2 breast oedema can result
in breast heaviness and pain. It can alsoinfluence body image and the fitting of abra and clothing.
Physical signsThe International Society ofLymphology3 has described thesuccessive stages by whichlymphoedema develops according to thephysical signs that evolve in the limbonce swelling appears.Foldi and Foldi4 describe the timebetween lymph node intervention andthe first appearance of swelling, duringwhich period the woman is ‘at risk’ ofdeveloping lymphoedema, but thecondition is in a subclinical or latencyperiod where swelling is not present.They found that this stage may last formany years, during which the transportcapacity of the lymphatics is reduced, butthey can still transport the lymph load.
Who is at risk of breast cancer
related lymphoedema?Any woman who has received breastcancer treatment involving surgery orradiotherapy to lymph node areas is atrisk of developing lymphoedema. Thelymph nodes most commonly involvedin breast cancer treatment include theaxillary lymph nodes and thesupraclavicular lymph nodes.Any patient who has a tumourobstructing the lymph node areas willalso be at risk of developinglymphoedema.Armer5 suggests that lymphoedemamay be under-recognised and under-diagnosed, because of a failure torecognise symptoms such as changes infeel and function as early indicators ofdeveloping lymphoedema.
This view is supported by Moffatt et al,6who suggest the true prevalence oflymphoedema may be underestimatedbecause many women may not bereceiving care for the condition or thesymptoms they are experiencing.
Risk factorsLymphoedema may develop early orafter a delayed time period, and it isnot always possible to predict whichwomen will go on to develop thecondition.Among the most important factorsinvolved in its development is surgeryin which lymph nodes are removed andfail to regenerate, and radiotherapy tolymph node areas that leads to scarringand decreased lymph drainage.Deo et al.7 suggest a link betweenpostoperative swelling that persists formore than two weeks and thedevelopment oflymphoedema. Otherpostoperative events thatare considered to beclinically relevant to therisk of developinglymphoedema includeseroma formation, cordingand postoperative infection,although there is limitedresearch to support these associations.In other studies of signs andsymptoms of lymphoedema, Armer andFui8 found that younger women aremore at risk of the development oflymphoedema, and Deo et al.7 observedthat women with an increased bodymass index were also at greater risk.
MINIMISING THE RISKLawenda et al.9 argue that themanagement of lymphoedema shouldbegin with efforts to prevent itsdevelopment. Two main principles areinvolved in achieving this: minimisingthe production of lymph, andminimising obstructions to itstransport. Women should be advised asearly as possible about how to takethem into account in their daily life.
Knowledge of which women areat risk, why they are at risk andwhat can be done to minimisethe risk is essential
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the development of early lymphoedemacan only be truly confirmed if baselinemeasurements of the arm have beentaken pre-operatively and are availablefor comparison.These may be recorded ascircumferential measurements using atape measure or with a bio-impedanceanalyser. Before an increase in armmeasurements can be considered asindicative of lymphoedema, Armer et al.5suggests that all women should be
advised to observe and be alert to earlysymptoms of developing lymphoedema,such as a heaviness, tightness or achingof the arm. By acknowledging suchsymptoms and seeking early advice, itmay still be possible to reverse anydeveloping lymphoedema.A non-randomised study by Campisiet al.11 advocated a three-monthpreventative treatment regimen forwomen at risk of lymphoedemafollowing breast cancer treatment. Thestudy group underwent manual lymph
drainage (MLD) every day for two weeksevery month, for a three-monthduration, and wore a compressiongarment daily whilst the control groupunderwent only clinical observation.The results suggested that theprogramme was of benefit, but theclinical, practical and financialimplications of such an intensivetreatment to prevent secondarylymphoedema is questionable.
MANAGING
LYMPHOEDEMAIf lymphoedema develops, acombination of approachescan be used to reduce andcontrol the swelling (see box).Emphasis is placed on thepatient’s active participationin managing the swelling ona daily basis.Above all, it is crucial thatstrategies to minimise the riskof developing lymphoedemashould be discussed as earlyas possible, in a sensitivemanner. Lymphoedema can have physical,psychological and psychosocialimplications for women followingbreast cancer treatment. Well-balancedadvice, tailored to the individual’scircumstances, will ensure that women donot develop a fear of the onset oflymphoedema and are able to maintaintheir quality of life whilst gaining anawareness of why they are at risk and whatthey can do to minimise that risk.All health care professionals caring forthis group of women should be able tomonitor routinely for lymphoedemafollowing breast cancer treatment, andpractice an approach of risk reduction,rather than waiting for the swelling toappear before taking action.
Based on a presentation at the Interconference
Breast Cancer Meeting IBCN2, Sarajevo, Bosnia
and Herzergovina,April 2009
Details of the references cited in this article can
be accessed at www.cancernurse.eu/
communication/eons_newsletter.html
Minimising lymph productionThe production of lymph is directlyproportional to blood flow. Consequently,any activities that involve an increase inblood flow can lead to increased lymphproduction and should therefore beminimised.These include exposure to extremes ofheat such as saunas, hot baths andsunbathing. The inflammatory responseto injury or trauma can also lead toincreased blood flow and lymphproduction, and women should beadvised to take great care of their skin inorder to minimise the risk of infection.Prolonged, vigorous and repetitiveactivities or sports that increase bloodflow constitute an important risk,particularly if these activities have notbeen taken up previously.A return to any previous activitiesshould be slow and controlled, withspecial attention paid to any symptomsof pain, aching or heaviness in the arm.
Minimising obstruction
of lymph transportThe obstruction of small lymph vesselsresponsible for lymph transport canoccur when wearing tight clothing orjewellery. Women should therefore dressonly in clothes that do not restrictmovement, and should wear jewellery onthe other arm or hand if it is too tight.Clinical activities such as monitoringblood pressure and using a tourniquetcan also damage superficial lymphvessels and should be avoided on thearm that is at risk of lymphoedema.Piller10 and Armer et al.5 observe that
Well-balanced advice, tailored tothe individual’s circumstances,will ensure that women... gainan awareness of why they are atrisk and what they can do tominimise that risk
Dougherty and Lister12 have outlined the four aspects of lymphoedema
management which are used following a full assessment of the patients needs:
 A skin care regime to minimise the risks of infection
 An exercise regime to promote lymph drainage
 Simple lymph drainage, based on the principles of manual lymph drainage
 Compression therapy to reduce and control the swelling
Four ways to manage lymphoedema
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